Adrenocortical cancer is a rare malignancy.
While surgery is the cornerstone of the management of localized disease, metastatic disease is hard to treat. Cytotoxic chemotherapy and mitotane have been utilized with a variable degree of benefit and few long-term responses. A growing understanding of the molecular pathogenesis of this malignancy as well as multidisciplinary and multi-institutional collaborative efforts will result in better defined targets and subsequently, effective novel therapies.
Written by:
Fay AP, Elfiky A, Teló GH, McKay RR, Kaymakcalan M, Nguyen PL, Vaidya A, Ruan DT, Bellmunt J, Choueiri TK. Are you the author?
Dana-Farber Cancer Institute, Boston, MA, United States; Joslin Diabetes Center, Boston, MA, United States; Brigham and Women's Hospital, Boston, MA, United States; Harvard Medical School, Boston, MA, United States. ;
Reference: Crit Rev Oncol Hematol. 2014 Jun 4. pii: S1040-8428(14)00088-2.
doi: 10.1016/j.critrevonc.2014.05.009
PubMed Abstract
PMID: 24958272
UroToday.com Adrenal and Kidney Conditions Section
